1093659-89-2

Ezetimibe-d₄ is intended for use as an internal standard for the quantification of ezetimibe by GC- or LC-MS. Ezetimibe inhibits intestinal cholesterol absorption by preventing cholesterol uptake by the Niemann-Pick C1-like 1 (NPC1L1) protein, a cholesterol transporter located in the apical membrane of enterocytes. Upon oral administration ezetimibe undergoes rapid glucuronidation in the intestine where its glucuronide binds NPC1L1. Ezetimibe exhibits ED₅₀ values of 0.0005-0.05 mg/kg in various animal models, selectively blocking cholesterol absorption without inhibiting pancreatic lipolytic enzyme activities in the intestinal lumen, affecting bile acid micelle solubilization of cholesterol, or interfering with the absorption of triglycerides, fatty acids, or bile acids.

Ezetimibe-d4 is the labeled analogue of Ezetimibe (E975000), an antihyperlipoproteinemic. A cholesterol absorption inhibitor.

[1] WANG D Q H. Regulation of intestinal cholesterol absorption.[J]. Annual review of physiology, 2007, 69: 221-248. DOI: 10.1146/annurev.physiol.69.031905.160725
[2] MARGARITA GARCIA-CALVO. The target of ezetimibe is Niemann-Pick C1-Like 1 (NPC1L1).[J]. Proceedings of the National Academy of Sciences of the United States of America, 2005: 8132-8137. DOI: 10.1073/pnas.0500269102
[3] THOMAS SUDHOP K von B. Cholesterol absorption inhibitors for the treatment of hypercholesterolaemia.[J]. Drugs, 2002, 62 16: 2333-2347. DOI: 10.2165/00003495-200262160-00002